An elderly hemodialytic case of recurrent esophageal cancer given combination chemotherapy with docetaxel and nedaplatin who showed temporal relief of swallowing disturbance

• Published in: Gan to kagaku ryoho Vol. 37; no. 5; p. 883
• Main Authors: Miura, Tomofumi, Hosojima, Yasuhiro, Nakamura, Junichiro, Yamada, Satoshi, Nakazawa, Yasuko, Ozeki, Yutaka, Miura, Tsutomu, Yanagi, Masahiko, Yamazaki, Hajime, Takahashi, Toru
• Format: Journal Article
• Language: Japanese
• Published: Japan 01.05.2010
• Subjects: Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols - therapeutic use; Deglutition - drug effects; Esophageal Neoplasms - complications; Esophageal Neoplasms - diagnostic imaging; Esophageal Neoplasms - drug therapy; Esophageal Neoplasms - pathology; Fatal Outcome; Humans; Male; Myocardial Infarction - complications; Neoplasm Recurrence, Local - complications; Neoplasm Recurrence, Local - diagnostic imaging; Neoplasm Recurrence, Local - drug therapy; Organoplatinum Compounds - administration & dosage; Organoplatinum Compounds - therapeutic use; Quality of Life; Renal Dialysis; Taxoids - administration & dosage; Taxoids - therapeutic use; Tomography, X-Ray Computed; Treatment Outcome
• ISSN: 0385-0684

An 82-year-old man was admitted for recurrent and unresectable esophageal cancer. His performance status was grade 2, although he was on hemodialysis due to chronic renal failure since 2003. Esophagogastroduodenoscopy revealed stenosis of esophagus by the recurrent tumor. After percutaneous endoscopic gastrostomy, he received biweekly combination chemotherapy with docetaxel (18 mg/m(2)) and nedaplatin (16 mg/m(2)). Hemodialysis was carried out one hour after termination of nedaplatin infusion. As severe adverse reactions due to anticancer-chemotherapy were not encountered, he could receive four courses of chemotherapy in our outpatient clinic. Difficulty in swallowing improved after the second course was finished. Finally, he died of acute myocardial infarction. In conclusion, combination chemotherapy with docetaxel and nedaplatin can be safely carried out for a patient with recurrent and unresectable esophageal cancer even on hemodialysis by appropriate down-dosing of anticancer agents.